Summary
Dr. Mehmet Oz, head of the Centers for Medicare and Medicaid Services, announced plans to limit access to gender-affirming care for minors. The Department of Health and Human Services proposed several actions to restrict this care, citing concerns about the costs and effects of procedures like phalloplasty. The measures are part of a broader effort by President Trump's administration to regulate transgender care for young people.
Key Facts
- Dr. Mehmet Oz criticized the high costs of gender-affirming procedures such as phalloplasty and scrotoplasty.
- The Department of Health and Human Services plans to restrict access to transgender care for minors.
- President Trump issued an executive order to stop federal funding for child gender transitions.
- Health Secretary Robert F. Kennedy Jr. labeled gender-affirming care for minors as malpractice.
- CMS plans to prevent hospitals that perform these procedures on minors from accessing Medicare and Medicaid programs.
- The FDA warned 12 companies about illegally marketing products aimed at treating gender dysphoria in children.
- A report by HHS found that procedures for gender dysphoria could have negative health effects, including infertility and surgical complications.
